Targeting claudins in cancer
- 28 May 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (9) , 723-738
Abstract
Epithelial-derived malignancies account for the majority of human tumours and present considerable treatment challenges owing to their heterogeneity, metastatic potential and resistance to therapy. The claudin family of tetra-transmembrane proteins was identified approximately 28 years ago as containing key regulators of epithelial function. These proteins are integral components of tight junctions, which control barrier integrity, selective channel permeability and cellular organization in epithelial tissues. Subsequent murine studies revealed that claudins also have tissue-specific physiological roles, whereas clinical studies demonstrated that their expression is frequently dysregulated in various cancers, highlighting their potential as therapeutic targets. In the past few decades, increasing efforts to exploit claudins in cancer therapy have led to the development of targeted molecules, including zolbetuximab, a first-in-class CLDN-18.2-targeted antibody for the treatment of gastric cancer, which has been recently approved by the United States Food and Drug Administration. This milestone emphasizes the therapeutic potential of targeting this protein family and its possible role in expanding treatment options for cancer. In this review, we discuss the evolving landscape of claudin-targeting therapeutics, examining key advances, emerging challenges and future prospects.Keywords
This publication has 145 references indexed in Scilit:
- 1419P Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102)Annals of Oncology, 2024
- A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumorsInvestigational New Drugs, 2022
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaAnnals of Oncology, 2021
- Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR/AKT/mTOR signalling pathway in hepatocellular carcinomaCell Biochemistry and Function, 2020
- Efficacy and safety evaluation of claudin‐4‐targeted antitumor therapy using a human and mouse cross‐reactive monoclonal antibodyPharmacology Research & Perspectives, 2016
- Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancersPflügers Archiv - European Journal of Physiology, 2016
- Claudin‐1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostateThe Prostate, 2007
- Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapyCancer Immunology, Immunotherapy, 2004
- Use of representational difference analysis to study the effect of TGFB on the expression profile of a pancreatic cancer cell lineGenes, Chromosomes and Cancer, 1999
- Evidence for Clostridium perfringens Enterotoxin (CPE) Inducing a Mitogenic and Cytokine Response In Vitro and a Cytokine Response In VivoCurrent Microbiology, 1999